As mentioned above, the MMR genes were significantly enriched in cluster 3, and comprised among others MSH6, MSH2 and MLH1 that have been associated with acquired treatment resistance to TMZ in recurrent gliomas when mutated or silenced otherwise [27]. This evidence concerns the gene MLH1 and central nervous system cancer.